Standard dosing ranges from 0.25 to 0.5 mg daily, while micro-dosing protocols typically use 0.1 to 0.15 mg injected subcutaneously once or twice daily
No bridging dose is needed
Waar eerder vooral GLP1-agonisten zoals semaglutide bekend waren, zien we nu een nieuwe generatie geneesmiddelen opkomen: dubbele GLP1/GIP-agonisten, met tirzepatide als bekendste voorbeeld
The Importance of Medical Necessity One of the key factors in determining insurance coverage for lipedema surgery is establishing medical necessity
Pharmaceuticals and Supplements Historical Agents Prescription Stimulants Literature summary Prescribing variations Combination Agents New Novel Prescription Agents (Qsymia, Contrave, Incivree) GLP-1 Agonists (Liraglutide and Semaglutide) GLP-1 Tips and Tricks Tirzepatide (Mounjaro and Zepbound) differences and benefits over GLP-1s Off-Label Mediations likely to be approved in 2027 New ORAL Prescription agents ** Oral Zepbound and Foundayo OTC Supplements Why Caffeine Does Not Work **Course includes automatic updates as needed to follow these developments** Analysis of Popular Diets Counting Calories The Low-Fat Mistake Low-Carb, High-Fat Low Glycemic Diets Glycemic Index vs Glycemic Load Low-Carb, High-Protein Ketosis Diets How to Achieve Ketosis Safely Physiology of Ketosis to Burn Fat Meal Replacements Dietary Recall Issues Diet Apps Practice Tips and Tricks Billing Insurance Handling the Reluctant, Resistant, and Defeated Weight Loss Patient Incorporating BHRT, Thyroid, GI Testing and NT Testing into Weight Loss How to take a Great Weight Loss History Forming a Partnership with the Patient Using Follow-up Visits for Continued Motivation and Compliance CME Accreditation Statement Evidence-Based Weight Loss Online CME Certification The AAFP has reviewed Evidence-Based Weight Loss and deemed it acceptable for up to 8.00 Enduring Materials, Self-Study AAFP Elective credit(s)
